CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Inclusion Criteria

• •Willing and able to provide, or have a legally authorized representative provide, written informed consent and HIPAA authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.
• •Histologically confirmed prostate cancer.
• •High volume metastatic disease (defined as the presence of visceral metastases or ≥3 bone lesions).
• •ADT for ≤3 months by day 1 of study chemotherapy; Prior episodes of ADT are allowed (i.e. ADT used previously in courses of radiation).
• •Testosterone \<50 ng/dL. Patients must continue primary ADT with an LHRH analogue if they have not undergone orchiectomy.
• •ECOG Performance Status 0 or 1 (see Appendix A)
• •Patient has adequate bone marrow and organ function as defined by the following laboratory values:
• •* Absolute neutrophil count ≥ 1.5 × 10\^9/L
• •* Platelets ≥ 100 × 10\^9/L
• •* Hemoglobin ≥ 9 g/dl
• •* Serum creatinine ≤ 1.5mg/dL or estimated creatinine clearance ≥ 50 ml/min
• •* In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN. If the patient has liver metastases, ALT and AST \<5 x ULN
• •* Total bilirubin \< ULN; or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert's Syndrome.
• •Sexually active males must use a condom during intercourse while taking study drugs and for 30 days after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. Fertile males must use a condom with spermicide (double barrier method).
• •Age ≥ 18 years